Type 1 diabetes (T1D) impacts nearly two million Americans, and by the time most people learn they have it, most of the body's insulin-producing cells...
Vous n'êtes pas connecté
Maroc - Times of India - Life & Style - 13/12/2024 17:13
Researchers at Mount Sinai are developing a revolutionary pill using harmine, a DYRK1A inhibitor, to regenerate insulin-producing beta cells in the pancreas. Harmine alone tripled beta cell mass, and combined with a GLP-1 agonist like Ozempic, increased it by 700%. The team discovered that alpha cells could potentially be transformed into beta cells, offering a new source for insulin production.
Type 1 diabetes (T1D) impacts nearly two million Americans, and by the time most people learn they have it, most of the body's insulin-producing cells...
A new oral PCSK9 inhibitor, enlicitide, offers a daily pill option for lowering LDL-C, a key cardiovascular disease risk factor. A clinical trial...
TUESDAY, Nov. 25, 2025 -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use with subsequent prepregnancy or early pregnancy discontinuation is...
For The Union-Tribune GLP one less for the road Apart from their widely celebrated effect at weight loss and diabetes management, GLP-1 drugs like...
TUESDAY, Nov. 25, 2025 — New clinical trial results bode well for what could be the first GLP-1 weight loss drug taken as a pill, not by...
Researchers at the Icahn School of Medicine at Mount Sinai have discovered how to reverse aging in blood-forming stem cells in mice by correcting...
Scientists at Cedars-Sinai have discovered that old and damaged blood vessel cells may be an important cause of metabolic disorders like diabetes....
Scientists at Cedars-Sinai have discovered that old and damaged blood vessel cells may be an important cause of metabolic disorders like diabetes....